AstraZeneca-Daiichi Breast Cancer Drug Cuts Disease Progression Or Death Risk By Almost 50%

  • AstraZeneca Plc AZN and Daiichi Sankyo's DSKYF Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy.
  • Financial Times wrote 'oncologists are hopeful a drug developed by AstraZeneca and Daiichi Sankyo will change how doctors treat the most common type of late-stage breast cancer."
  • Detailed results from the DESTINY-Breast04 Phase 3 trial showed that Enhertu reduced the risk of disease progression or death versus chemotherapy by 49% in patients with HER2-low metastatic breast cancer with HR-positive disease.
  • Related: Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer.
  • A median progression-free survival (PFS) of 10.1 months was seen in patients treated with Enhertu compared to 5.4 months with chemotherapy.
  • Results also showed a 36% reduction in the risk of death with Enhertu compared to chemotherapy in patients with HR-positive disease with a median overall survival (OS) of 23.9 months with Enhertu versus 17.5 months with chemotherapy.
  • Price Action: AZN shares are down 0.97% at $65.06 during the premarket session on the last check Monday.

Posted In: BriefsBiotechLarge CapNewsHealth CareTop StoriesGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.